Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

NLK

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101750

Synonyms

Historical Background

The protein kinase NLK was originally identified as nemo, a gene involved in Drosophila melanogaster eye development. D. melanogaster compound eyes are made up of hexagonal units called ommatidia. A mutation in nemo affects the movement of ommatidia cells, causing them to acquire a squared shape (Choi and Benzer 1994) which is reflected in the name “nemo,” Korean for square. In 1998, Brott et al. isolated the mouse homolog of nemo and named it “Nemo-like kinase (NLK).” Meneghini et al. (1999) and Rocheleau et al. (1999) found that the Caenorhabditis elegans loss-of-intestine-1 (lit-1) mutant, which lacks the endoderm, has a mutation in a homolog of NLK. This homolog phosphorylates Posterior pharynx defect protein 1 (POP-1) to relieve POP-1-mediated inhibition of gene expression required for endoderm formation. POP-1 is a homolog of the mammalian T-cell factor/lymphoid enhancer factor (Tcf/Lef), a key component of the Wnt/β-catenin signaling pathway. Ishitani et al. (1999) also discovered that mammalian NLK could phosphorylate and inhibit Tcf/Lef in human embryonic kidney 293 (HEK293) cells. This was the first discovery of a molecular function of NLK.

NLK is evolutionarily conserved from C. elegans to humans (Fig. 1). Invertebrates, chickens, and mammals possess only one NLK gene, whereas amphibians (Xenopus laevis/African clawed frog and X. tropicalis/Western clawed frog) and fish (Danio rerio/zebrafish and Oryzias latipes/medaka) possess two NLK genes, type-I NLK (NLK1/Nlk1) and type-II NLK (NLK2/Nlk2). Type-II NLK, but not type-I NLK, contains conserved regions at the N-terminus (histidine (His)-rich) and C-terminus (Fig. 1b) (Ota et al. 2012; Ishitani and Ishitani 2013). All NLK proteins exhibit high homology to mitogen-activated protein kinases (MAPKs). Mouse NLK (type-II) exhibits a 54.5% amino acid similarity to mouse MAPK1 (Brott et al. 1998). Interestingly, typical MAPKs, including MAPK1, contain a characteristic MAPK-activating phosphorylation sequence, Thr-Xxx-Tyr (TXY), in the activation loop, whereas NLKs do not have a TXY motif in their activation loop. Instead, they harbor a Thr-Xxx-Glu (TQE) sequence at an analogous site (Brott et al. 1998). Therefore, NLK is considered an atypical MAPK.
NLK, Fig. 1

NLK protein family. (a) Phylogenetic analysis of NLK homologs obtained by comparing amino acid sequences. Vertebrate type-I and type-II NLKs are shown in blue and red, respectively. (b) Schematic diagrams of type-I and type-II NLKs. Note that type-II NLKs, but not type-I NLKs, have conserved histidine-rich (His-rich) and C-terminal regions, which are indicated by orange and red boxes, respectively

Roles of NLK-Mediated Phosphorylation in the Nucleus

Given the similarity between NLK and MAPKs, NLK is thought to function as a proline (Pro)-directed kinase that phosphorylates proteins on a serine (Ser) or threonine (Thr) residue immediately preceding a Pro. In practice, NLK phosphorylates Ser and Thr residues of Ser-Pro and Thr-Pro sequences on a variety of signaling molecules, such as the Tcf/Lef family of proteins, Notch1, and c-Myb (Fig. 2; Ishitani et al. 2003a, 2010; Kanei-Ishii et al. 2004; Ota et al. 2012). However, the exact consensus target sequence of NLK has not been characterized.
NLK, Fig. 2

NLK targets. Vertebrate cytoplasmic and cytoskeletal NLK substrates are indicated in orange, and transcriptional regulators phosphorylated by NLK are indicated in green. Drosophila Nemo substrates are indicated in gray

NLK, Fig. 3

Mechanisms of NLK activation. NGF signaling stimulates the dissociation of NLK from a large Golgi complex, inducing its dimerization and consequent autophosphorylation on Thr-286

As mentioned above, C. elegans POP-1, a member of the Tcf/Lef protein family, was identified as the first NLK substrate. NLK phosphorylates and regulates vertebrate Tcf/Lefs. Vertebrates have four Tcf/Lef members (five in zebrafish), including Tcf7 (Tcf1), Tcf7L1 (Tcf3), Tcf7L2 (Tcf4), and Lef1. NLK phosphorylates Tcf7L1, Tcf7L2, and Lef1 on conserved Ser/Thr-Pro sequences (e.g., Thr155-Pro156 and Ser166-Pro167 on human Lef1). Although Tcf7 contains such conserved Ser/Thr-Pro sequences, NLK is unable of phosphorylating it (Ishitani et al. 1999, 2003a; Ota et al. 2012). NLK-mediated Tcf/Lef phosphorylation positively or negatively regulates Tcf/Lef activity. In human embryonic kidney 293 (HEK293) and cervical cancer (HeLa) cells, overexpression of NLK reduced DNA binding and inhibited the transcriptional activity of Tcf7L2 and Lef1 (Ishitani et al. 1999, 2003a; Ota et al. 2012). In addition, Yamada et al. (2006) reported that NLK promoted NLK-associated RING finger protein (NARF)-mediated ubiquitination and the subsequent proteasomal degradation of Tcf7L2 and Lef1 in HEK293 cells. On the contrary, NLK is essential for the activation of Lef1-mediated transcription in neural progenitor cells (NPCs) and related cells. In NPC-like mammalian cell lines, rat pheochromocytoma tumor (PC12) cells, mouse neuroblastoma (neuro-2a) cells, and zebrafish midbrain NPCs, histone deacetylase HDAC1 binds to Lef1 and inhibits its transcriptional activity. NLK-mediated Lef1 phosphorylation stimulates the dissociation of Lef1 from HDAC1, thereby promoting Lef1 transcriptional activity. Such positive regulation promotes the proliferation of zebrafish midbrain NPCs and consequent midbrain size expansion. Consistent with this finding, knockdown of zebrafish type-II NLK, Nlk2, reduced Lef1 activity and cell proliferation in the developing midbrain, whereas co-knockdown of HDAC1 reversed this effect (Ota et al. 2012).

A biochemical screening for NLK substrates yielded the Notch signaling transcription factors, Notch1 and Notch3 (Ishitani et al. 2010). NLK phosphorylates the intracellular domain of Notch1 (Notch1-ICD) on seven Ser residues within conserved Ser-Pro motifs. Phosphorylation at these sites prevents the formation of a ternary complex between Notch1-ICD, the DNA-binding factor CSL (CBF-1, Suppressor of Hairless, and LAG-1) and a member of the Mastermind family of transcriptional coactivators. Consequently, Notch1-ICD-mediated gene expression is inhibited in a variety of mammalian cultures, including HEK293, HeLa, neuro-2a, PC12, and the colorectal cancer SW480 cells. NLK can also regulate Notch1 activity in vivo. In zebrafish, Notch1 signaling maintains NPCs in an undifferentiated state, preventing their commitment to neurons. Knockdown of zebrafish type-I NLK, Nlk1, enhanced Notch1 signaling and blocked NPC differentiation in the zebrafish neural plate. Accordingly, Nlk1-mediated downregulation of Notch1 signaling was likely to be essential for proper neurogenesis in the zebrafish neural plate (Ishitani et al. 2010). A recent report showed that NLK-mediated Notch1 inhibition contributed to natural killer cell development (Cichocki et al. 2011). Thus, NLK negatively regulates Notch1 signaling in vivo. In contrast, the role of NLK-mediated Notch3 phosphorylation remains unclear, although Ishitani et al. (2010) previously reported that NLK could promote Notch3 activity in a kinase-dependent manner in neuro-2a cells.

NLK can phosphorylate other families of transcriptional regulators, including c-Myb, signal transducer and activator of transcription 3 (STAT3), Forkhead box protein O1 (Foxo1), and MEF2A (Fig. 2). c-Myb is a transcription factor that regulates hematopoietic stem cell proliferation and differentiation. NLK promotes c-Myb degradation via phosphorylation of 15 Ser/Thr-Pro motifs in monkey kidney CV-1 cells (Kanei-Ishii et al. 2004). Kurahashi et al. (2005) showed that NLK could phosphorylate the c-Myb-related protein A-Myb, thus promoting the dissociation of A-Myb from the transcriptional coactivator CBP and attenuation of A-Myb-dependent transcription. STAT3 is an important transcription factor that mediates cytokine signaling. NLK phosphorylates STAT3 on Ser-727 to promote downstream interleukin-6 (IL-6) signaling in human hepatocellular carcinoma (HepG2) cells (Kojima et al. 2005). Ohkawara et al. (2004) reported that X. laevis type-I NLK, NLK1, regulated mesoderm formation via STAT3 Ser-727 phosphorylation. Kim et al. (2010) showed that NLK phosphorylates Foxo1, which controlled the expression of genes involved in apoptosis, cell cycle, stress response, longevity, DNA repair, and glucose metabolism. NLK-mediated phosphorylation negatively regulates the transcriptional activity of Foxo1 by promoting its nuclear export in monkey kidney (Cos-1) cells. Satoh et al. (2007) reported that X. laevis NLK1 phosphorylated the MEF2A transcription factor to control embryonic anterior head formation. Interestingly, Ota et al. (2011) showed that NLK1 overexpression could induce the phosphorylation of key regulators of translational control, including Pumilio1, Pumilio2, and cytoplasmic polyadenylation element-binding protein (CPEB) in X. laevis oocytes, suggesting that NLK may phosphorylate not only transcriptional but also translational regulators.

Recent D. melanogaster genetic analyses have revealed that Nemo phosphorylates a variety of transcriptional regulators, such as even-skipped (Eve), mothers against decapentaplegic (Mad), eyes absent (Eya), and period (Fig. 2). The phosphorylation of the Eve homeobox transcription repressor contributes to embryonic segment patterning (Braid et al. 2010). Mad is the D. melanogaster homolog of the bone morphogenetic protein (BMP) signaling transcription factor Smad. Mad phosphorylation negatively regulates BMP signaling during wing development (Zeng et al. 2007). Eya is a transcriptional regulator essential for eye development, which is activated by Nemo-dependent phosphorylation (Morillo et al. 2012). Period is a circadian clock component, whose stability is enhanced by Nemo-dependent phosphorylation (Chiu et al. 2011).

Occasionally, NLK can work without phosphorylating its substrate. NLK binds to ATF5, a member of the ATF/CREB protein family of transcription factors, thus stabilizing ATF5 in a kinase-independent manner downstream of IL-1 signaling (Zhang et al. 2015). Finally, NLK stabilizes and activates the transcription factor p53, albeit without phosphorylating it, in response to DNA damage (Zhang et al. 2014). Thus, NLK plays a variety of roles in the nucleus.

Roles of NLK-Mediated Phosphorylation Outside the Nucleus

Given that in many mammalian cell lines, exogenous NLK localizes mainly to the nucleus (Brott et al. 1998; Ishitani et al. 2009), nuclear functions of NLK have been well studied. Interestingly, our immunostaining analyses revealed that endogenous NLK localized to the cytoplasm and not to the nucleus in neuro-2a, PC12, HEK293, and HeLa cells. Moreover, stimulation with nerve growth factor (NGF) not only promoted the translocation of endogenous NLK into the nucleus and leading edges of the cell, but also induced the enzymatic activation of NLK (Ishitani et al. 2009; T.I. and S.I. unpublished observations). These findings suggest that NLK functions not only in the nucleus but also in the cytoplasm and near the plasma membrane. Consistent with this idea, Ishitani et al. (2009) showed that NLK phosphorylated the focal adhesion adaptor protein paxillin on Ser-126 and the microtubule-associated protein 1B (MAP1B) at the leading edge of NGF-treated PC12 cells (Fig. 2). D. melanogaster Nemo localizes to the plasma membrane and phosphorylates the β-catenin homolog armadillo during eye development (Fig. 2; Mirkovic et al. 2011), indicating that invertebrate NLK functions also near the plasma membrane. However, because mammalian NLK cannot phosphorylate β-catenin (Ishitani et al. 2003a; T.I. and S.I. unpublished observations), the relationship between NLK and β-catenin does not appear to be evolutionarily conserved.

Recently, Yuan et al. (2015) have reported that NLK plays an important role in stress response in the cytoplasm. In nutrient-rich conditions, the Rag1 GTPase binds to and activates the mechanistic target of rapamycin (mTORC1) and promotes cell growth by stimulating transcription, translation, and anabolism. To counteract osmotic and oxidative stress, NLK phosphorylates Raptor, an mTORC1 subunit, on Ser-863 (Fig. 2) and disrupts the interaction between Rag1 and mTORC1, thus inhibiting mTORC1 activation.

Regulation of NLK Activity

As described above, NLK is an atypical MAPK. The activity of typical MAPKs is tightly regulated, and overexpression is insufficient to activate them. MAPK kinase (MAPKK)-dependent phosphorylation of Thr and Tyr residues in the TXY motif is required to activate typical MAPKs. However, overexpression is sufficient for activation of NLK kinase (Brott et al. 1998; Ishitani et al. 2011), suggesting that NLK does not require the intervention of upstream kinases. Given that the negatively charged glutamic acid can mimic a phosphorylated amino acid, it is possible that Ser/Thr kinase(s)-mediated phosphorylation of Thr-286 in the TQE sequence leads to NLK activation. Ishitani et al. (2011) showed that exogenous NLK formed homodimers and then autophosphorylated Thr-286 in a trans-manner in HEK293 cells. Substitution of Thr-286 with a valine or phosphatase treatment reduced NLK kinase activity. The conserved C-terminal domain is required for NLK homodimerization. Mutation of Cys-425 in the C-terminal domain of NLK prevented NLK dimerization and hampered its kinase activity (Ishitani et al. 2011). Thus, NLK can be self-activated via homodimerization. Ishitani et al. (2011) also reported that inactive endogenous NLK was trapped in large heterologous complexes around the Golgi in unstimulated PC12 cells. Addition of NGF stimulated the release of NLK from the complex, its homodimerization leading to autophosphorylation on Thr-286 and subsequent activation (Ishitani et al. 2011) (Fig. 3). However, the detailed nature of the large Golgi complex remains unclear.

In addition to NGF, several extracellular factors have been identified as NLK activators. Endogenous NLK can be activated by epidermal growth factor (EGF) or Wnt-3a in PC12 cells (Ishitani et al. 2009; Ota et al. 2012) and by Activin A or Wnt-5a in HEK293 cells (Ohkawara et al. 2004; Ishitani et al. 2003b). Exogenous NLK can be activated by treatment with IL-6 or transforming growth factor-β (TGF-β) in HepG2 cells (Kojima et al. 2005) and by osmotic or oxidative stress in HEK293 cells (Yuan et al. 2015). Several intracellular modulators of NLK activity have also been identified. One of these is TAK1 MAP3K, which promotes the autophosphorylation and activation of NLK/LIT-1 in C. elegans (Meneghini et al. 1999; Ishitani et al. 1999). TAK1 appears to activate NLK indirectly. Kanei-Ishii et al. (2004) reported that TAK1 phosphorylated and activated homeodomain-interacting protein kinase 2 (Hipk2), which then bound to and activated NLK. Ohnishi et al. (2010) reported that p38 MAPK phosphorylated and activated NLK downstream of TAK1. Although TAK1 is involved in Wnt-5a- and IL-6-dependent activation of NLK (Ishitani et al. 2003b; Kojima et al. 2005), NGF and EGF activate NLK in a TAK1-independent manner through Ras GTPase (Ishitani et al. 2009; T.I. and S.I. unpublished observations). Kim et al. (2012) recently described dimerization partner 1 (DP1) as an inhibitor of NLK. DP1 binds directly to and inhibits NLK, consequently enhancing Wnt/β-catenin signaling in X. laevis early embryos.

NLK is regulated at the protein level by noncoding RNAs. MicroRNAs miR-181a and miR-181b reduce NLK protein levels and prevent NLK-mediated suppression of Notch signaling, thereby promoting human natural killer cell development in vitro (Cichocki et al. 2011). In hepatocellular carcinoma (HCC) cell lines, miR-181 family members (miRNA-181a/b/c/d) and miR-101 negatively regulate NLK expression (Ji et al. 2009; Shen et al. 2014). In addition, miR-288a inhibits NLK expression in rat cardiomyocyte (H9C2) cells (Huang et al. 2016). Furthermore, a cancer-related long noncoding RNA, HOTAIR, has been shown to inhibit NLK transcription in glioma cells (Zhou et al. 2015). Because the regulation of NLK enzymatic activity is relatively loose, organisms may have evolved a variety of systems to control NLK expression.

To better understand NLK function and regulation, it would be advantageous to develop specific chemical inhibitors against NLK. At present, NLK activation can be blocked only with lithium chloride and lithium carbonate (Ishitani et al. 2009; T.I. and S.I. unpublished observations). However, lithium is not a specific inhibitor, and development of specific NLK inhibitors is awaited.

Physiological Roles of NLK

The NLK gene family plays important roles in central nervous system (CNS) development in vertebrates. X. laevis NLK1 regulates anterior brain formation through MEF2A phosphorylation in early embryos (Satoh et al. 2007). D. rerio Nlk1 controls neural plate anterior-posterior patterning via positive regulation of Wnt/β-catenin signaling (Thorpe and Moon 2004) and promotes the differentiation of NPCs into neurons by blocking Notch signaling (Ishitani et al. 2010). In contrast, D. rerio Nlk2 contributes to midbrain size expansion through Lef1 phosphorylation and consequent stimulation of Wnt/β-catenin signaling (Ota et al. 2012). Kortenjann et al. (2001) reported that type-II NLK-deficient mice suffered from various neurological abnormalities such as cerebellar ataxia, indicating that type-II NLK might contribute to brain development in mammals. Thus, type-I NLKs seem to control early brain (neural plate) development, whereas type-II NLK appears to regulate the later stages.

Mouse type-II NLK is also involved in non-neural tissue development, including lung morphogenesis, adipogenesis, and hematopoiesis. Ke et al. (2016) reported that type-II NLK-deficient mice became cyanotic because of lung maturation defects, exhibiting elevated vascular endothelial growth factor (VEGF) expression, and small and compressed alveoli (Ke et al. 2016). Kortenjann et al. (2001) showed that bone marrow adipogenesis was enhanced, whereas the number of hematopoietic cells was reduced in type-II NLK-deficient mice.

NLK in Disease

A number of studies have reported a correlation between cancer development and NLK expression or activity. NLK negatively regulates the expression of androgen receptor (AR) and the nuclear steroid hormone receptor Nurr1, both of which correlate with prostate cancer progression. Consistent with this, NLK expression has been found to decrease during prostate cancer progression (Emami et al. 2009; Wang et al. 2016). Similarly, NLK expression is inversely correlated with glioma grade (Cui et al. 2011; Sa et al. 2015). NLK can negatively regulate Wnt/β-catenin signaling through Lef1 phosphorylation and suppress mesenchymal activity of glioma cells; however, in high-grade gliomas in which NLK expression is very low, Wnt/β-catenin signaling and mesenchymal activities are upregulated (Sa et al. 2015). Thus, NLK exhibits tumor suppressor activities in this type of cancer. By contrast, in HCCs, upregulation of NLK enhances the expression of cyclin D1, a core component of cell cycle regulation. NLK RNAi has been reported to reduce HCC viability (Jung et al. 2010). In addition, Mendes-Pereira et al. (2012) showed that NLK RNAi reduced the viability of PTEN-deficient breast, colorectal, bladder, and ovary cancer, as well as in melanoma cells. Consequently, NLK represents a potential therapeutic target for these tumor types, whose treatment would benefit from the existence of specific chemical NLK inhibitors.

A recent study using a mouse disease model has revealed that NLK is involved in polyglutamine diseases, including spinal and bulbar muscular atrophy (SBMA) and spinocerebellar ataxia type 1(SCA1). Polyglutamine diseases represent a group of neurodegenerative disorders caused by expanded CAG repeats encoding a long polyQ tract in the corresponding proteins. SBMA is caused by polyQ-expanded AR (polyQ-AR), resulting in motor neuron degeneration and muscle bulk loss. SCA1 is caused by polyQ-expanded Ataxin1 (polyQ-Ataxin1) and leads to cerebellum and motor neuron degeneration. Interestingly, Lim and coworkers at Yale University reported that NLK phosphorylated polyQ-AR and polyQ-Ataxin1 (Fig. 2). Moreover, loss of one copy of the NLK gene rescued neuropathological phenotypes in SBMA and SCA1 model mice (Ju et al. 2013; Todd et al. 2015). Although the mechanisms by which NLK promotes SBMA and SCA1 are not fully understood, NLK may be a potential target for SBMA and SCA1 therapy.

Summary

NLK is an evolutionarily conserved atypical MAPK, which plays multifaceted roles in invertebrate and vertebrate development. NLK controls gene expression and cytoskeletal architecture by phosphorylating and regulating a variety of cell signaling components and cytoskeleton-associated proteins. As a result, it contributes to cell growth, proliferation, differentiation, and morphological changes during early embryonic patterning, brain development, lung morphogenesis, adipogenesis, and hematopoiesis. Although activated NLK phosphorylates many substrates, it is unlikely that it does so simultaneously. Instead, NLK probably phosphorylates and regulates specific substrates depending on the context. However, the detailed mechanisms of such selective regulation are still not clear. What is partly known is the process of NLK activation: NLK is released from a large Golgi complex in response to upstream stimulation, leading to dimerization and self-activation via autophosphorylation on Thr-286. However, the nature of this large complex and the mechanism by which NLK dissociates from it remain unclear, and these will be the focus of future studies. Recent reports have shown that NLK inhibition can ameliorate tumorigenesis and neurodegenerative diseases. Although specific chemical inhibitors against NLK have not been reported yet, they may be a useful tool not only in basic biological research but also in the treatment of multiple diseases.

References

  1. Braid LR, Lee W, Uetrecht AC, Swarup S, Papaianni G, Heiler A, Verheyen EM. Nemo phosphorylates even-skipped and promotes eve-mediated repression of odd-skipped in even parasegments during Drosophila embryogenesis. Dev Biol. 2010;343:178–89. doi:10.1016/j.ydbio.2010.04.008.PubMedCrossRefGoogle Scholar
  2. Brott BK, Pinsky BA, Erikson RL. Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. Proc Natl Acad Sci U S A. 1998;95:963–8.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Chiu JC, Ko HW, Edery I. NEMO/NLK phosphorylates PERIOD to initiate a time-delay phosphorylation circuit that sets circadian clock speed. Cell. 2011;145:357–70. doi:10.1016/j.cell.2011.04.002.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Choi KW, Benzer S. Rotation of photoreceptor clusters in the developing Drosophila eye requires the nemo gene. Cell. 1994;78:125–36.PubMedCrossRefGoogle Scholar
  5. Cichocki F, Felices M, McCullar V, Presnell SR, Al-Attar A, Lutz CT, Miller JS. Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. J Immunol. 2011;187:6171–5. doi:10.4049/jimmunol.1100835.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Cui G, Li Z, Shao B, Zhao L, Zhou Y, Lu T, Wang J, Shi X, Wang J, Zuo G, Zhu W, Shen A. Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci. 2011;18:271–5. doi:10.1016/j.jocn.2010.05.037.PubMedCrossRefGoogle Scholar
  7. Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL, Corey E. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate. 2009;69:1481–92. doi:10.1002/pros.20998.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Huang Y, Yang Y, He Y, Huang C, Meng X, Li J. MicroRNA-208a potentiates angiotensin II-triggered cardiac myoblasts apoptosis via inhibiting Nemo-like kinase (NLK). Curr Pharm Des. 2016;22:4868–75.PubMedCrossRefGoogle Scholar
  9. Ishitani T, Ishitani S. Nemo-like kinase, a multifaceted cell signaling regulator. Cell Signal. 2013;25:190–7. doi:10.1016/j.cellsig.2012.09.017.PubMedCrossRefGoogle Scholar
  10. Ishitani T, Ninomiya-Tsuji J, Nagai S, Nishita M, Meneghini M, Barker N, Waterman M, Bowerman B, Clevers H, Shibuya H, Matsumoto K. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature. 1999;399:798–802. doi:10.1038/21674.PubMedCrossRefGoogle Scholar
  11. Ishitani T, Ninomiya-Tsuji J, Matsumoto K. Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling. Mol Cell Biol. 2003a;23:1379–89.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J, Matsumoto K. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol. 2003b;23:131–9.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Ishitani T, Ishitani S, Matsumoto K, Itoh M. Nemo-like kinase is involved in NGF-induced neurite outgrowth via phosphorylating MAP1B and paxillin. J Neurochem. 2009;111:1104–18. doi:10.1111/j.1471-4159.2009.06400.x.PubMedCrossRefGoogle Scholar
  14. Ishitani T, Hirao T, Suzuki M, Isoda M, Ishitani S, Harigaya K, Kitagawa M, Matsumoto K, Itoh M. Nemo-like kinase suppresses Notch signalling by interfering with formation of the Notch active transcriptional complex. Nat Cell Biol. 2010;12:278–85. doi:10.1038/ncb2028.PubMedGoogle Scholar
  15. Ishitani S, Inaba K, Matsumoto K, Ishitani T. Homodimerization of Nemo-like kinase is essential for activation and nuclear localization. Mol Biol Cell. 2011;22:266–77. doi:10.1091/mbc.E10-07-0605.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HY, Tang ZY, Croce CM, Wang XW. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50:472–80. doi:10.1002/hep.22989.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Ju H, Kokubu H, Todd TW, Kahle JJ, Kim S, Richman R, Chirala K, Orr HT, Zoghbi HY, Lim J. Polyglutamine disease toxicity is regulated by Nemo-like kinase in spinocerebellar ataxia type 1. J Neurosci. 2013;33:9328–36. doi:10.1523/JNEUROSCI.3465-12.2013.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Park WS, Lee JY, Nam SW. Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem. 2010;110:687–96. doi:10.1002/jcb.22579.PubMedCrossRefGoogle Scholar
  19. Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J, Nomura T, Ishitani T, Kishida S, Kokura K, Kurahashi T, Ichikawa-Iwata E, Kim Y, Matsumoto K, Ishii S. Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev. 2004;18:816–29. doi:10.1101/gad.1170604.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Ke H, Masoumi KC, Ahlqvist K, Seckl MJ, Rydell-Törmänen K, Massoumi R. Nemo-like kinase regulates the expression of vascular endothelial growth factor (VEGF) in alveolar epithelial cells. Sci Rep. 2016;6. doi:10.1038/srep23987.Google Scholar
  21. Kim S, Kim Y, Lee J, Chung J. Regulation of FOXO1 by TAK1-Nemo-like kinase pathway. J Biol Chem. 2010;285:8122–9. doi:10.1074/jbc.M110.101824.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Kim WT, Kim H, Katanaev VL, Joon Lee S, Ishitani T, Cha B, Han JK, Jho EH. Dual functions of DP1 promote biphasic Wnt-on and Wnt-off states during anteroposterior neural patterning. EMBO J. 2012;31:3384–97. doi:10.1038/emboj.2012.181.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Kojima H, Sasaki T, Ishitani T, Iemura S, Zhao H, Kaneko S, Kunimoto H, Natsume T, Matsumoto K, Nakajima K. STAT3 regulates Nemo-like kinase by mediating its interaction with IL-6-stimulated TGFbeta-activated kinase 1 for STAT3 Ser-727 phosphorylation. Proc Natl Acad Sci U S A. 2005;102:4524–9. doi:10.1073/pnas.0500679102.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Kortenjann M, Nehls M, Smith AJ, Carsetti R, Schüler J, Köhler G, Boehm T. Abnormal bone marrow stroma in mice deficient for nemo-like kinase, Nlk. Eur J Immunol. 2001;31:3580–7. doi:10.1002/1521-4141(200112)31:12<3580::AID-IMMU3580>3.0.CO;2-N.PubMedCrossRefGoogle Scholar
  25. Kurahashi T, Nomura T, Kanei-Ishii C, Shinkai Y, Ishii S. The Wnt-NLK signaling pathway inhibits A-Myb activity by inhibiting the association with coactivator CBP and methylating histone H3. Mol Biol Cell. 2005;16:4705–13. doi:10.1091/mbc.E05-05-0470.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Mendes-Pereira AM, Lord CJ, Ashworth A. NLK is a novel therapeutic target for PTEN deficient tumour cells. PLoS One. 2012;7:e47249. doi:10.1371/journal.pone.0047249.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Meneghini MD, Ishitani T, Carter JC, Hisamoto N, Ninomiya-Tsuji J, Thorpe CJ, Hamill DR, Matsumoto K, Bowerman B. MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in Caenorhabditis elegans. Nature. 1999;399:793–7. doi:10.1038/21666.PubMedCrossRefGoogle Scholar
  28. Mirkovic I, Gault WJ, Rahnama M, Jenny A, Gaengel K, Bessette D, Gottardi CJ, Verheyen EM, Mlodzik M. Nemo kinase phosphorylates β-catenin to promote ommatidial rotation and connects core PCP factors to E-cadherin-β-catenin. Nat Struct Mol Biol. 2011;18:665–72. doi:10.1038/nsmb.2049.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Morillo SA, Braid LR, Verheyen EM, Rebay I. Nemo phosphorylates Eyes absent and enhances output from the Eya-Sine oculis transcriptional complex during Drosophila retinal determination. Dev Biol. 2012;365:267–76. doi:10.1016/j.ydbio.2012.02.030.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Ohkawara B, Shirakabe K, Hyodo-Miura J, Matsuo R, Ueno N, Matsumoto K, Shibuya H. Role of the TAK1-NLK-STAT3 pathway in TGF-beta-mediated mesoderm induction. Genes Dev. 2004;18:381–6. doi:10.1101/gad.1166904.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Ohnishi E, Goto T, Sato A, Kim MS, Iemura S, Ishitani T, Natsume T, Ohnishi J, Shibuya H. Nemo-like kinase, an essential effector of anterior formation, functions downstream of p38 mitogen-activated protein kinase. Mol Cell Biol. 2010;30:675–83. doi:10.1128/MCB.00576-09.PubMedCrossRefGoogle Scholar
  32. Ota R, Kotani T, Yamashita M. Possible involvement of Nemo-like kinase 1 in Xenopus oocyte maturation as a kinase responsible for Pumilio1, Pumilio2, and CPEB phosphorylation. Biochemistry. 2011;50:5648–59. doi:10.1021/bi2002696.PubMedCrossRefGoogle Scholar
  33. Ota S, Ishitani S, Shimizu N, Matsumoto K, Itoh M, Ishitani T. NLK positively regulates Wnt/β-catenin signalling by phosphorylating LEF1 in neural progenitor cells. EMBO J. 2012;31:1904–15. doi:10.1038/emboj.2012.46.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Rocheleau CE, Yasuda J, Shin TH, Lin R, Sawa H, Okano H, Priess JR, Davis RJ, Mello CC. WRM-1 activates the LIT-1 protein kinase to transduce anterior/posterior polarity signals in C. elegans. Cell. 1999;97:717–26.PubMedCrossRefGoogle Scholar
  35. Sa JK, Yoon Y, Kim M, Kim Y, Cho HJ, Lee JK, Kim GS, Han S, Kim WJ, Shin YJ, Joo KM, Paddison PJ, Ishitani T, Lee J, Nam DH. In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma. Oncotarget. 2015;6:20145–59. doi:10.18632/oncotarget.3980.PubMedPubMedCentralCrossRefGoogle Scholar
  36. Satoh K, Ohnishi J, Sato A, Takeyama M, Iemura S, Natsume T, Shibuya H. Nemo-like kinase-myocyte enhancer factor 2A signaling regulates anterior formation in Xenopus development. Mol Cell Biol. 2007;27:7623–30. doi:10.1128/MCB.01481-07.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Shen Q, Bae HJ, Eun JW, Kim HS, Park SJ, Shin WC, Lee EK, Park S, Park WS, Lee JY, Nam SW. MiR-101 functions as a tumor suppressor by directly targeting nemo-like kinase in liver cancer. Cancer Lett. 2014;344:204–11. doi:10.1016/j.canlet.2013.10.030.PubMedCrossRefGoogle Scholar
  38. Thorpe CJ, Moon RT. Nemo-like kinase is an essential co-activator of Wnt signaling during early zebrafish development. Development. 2004;131:2899–909. doi:10.1242/dev.01171.PubMedCrossRefGoogle Scholar
  39. Todd TW, Kokubu H, Miranda HC, Cortes CJ, La Spada AR, Lim J. Nemo-like kinase is a novel regulator of spinal and bulbar muscular atrophy. Elizab Theatr. 2015;4:e08493. doi:10.7554/eLife.08493.Google Scholar
  40. Wang J, Yang ZH, Chen H, Li HH, Chen LY, Zhu Z, Zou Y, Ding CC, Yang J, He ZW. Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer. BMC Cancer. 2016;16:257. doi:10.1186/s12885-016-2291-4.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Yamada M, Ohnishi J, Ohkawara B, Iemura S, Satoh K, Hyodo-Miura J, Kawachi K, Natsume T, Shibuya H. NARF, an nemo-like kinase (NLK)-associated ring finger protein regulates the ubiquitylation and degradation of T cell factor/lymphoid enhancer factor (TCF/LEF). J Biol Chem. 2006;281:20749–60. doi:10.1074/jbc.M602089200.PubMedCrossRefGoogle Scholar
  42. Yuan HX, Wang Z, FX Y, Li F, Russell RC, Jewell JL, Guan KL. NLK phosphorylates Raptor to mediate stress-induced mTORC1 inhibition. Genes Dev. 2015;29:2362–76. doi:10.1101/gad.265116.115.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Zeng YA, Rahnama M, Wang S, Sosu-Sedzorme W, Verheyen EM. Drosophila Nemo antagonizes BMP signaling by phosphorylation of Mad and inhibition of its nuclear accumulation. Development. 2007;134:2061–71. doi:10.1242/dev.02853.PubMedCrossRefGoogle Scholar
  44. Zhang HH, Li SZ, Zhang ZY, XM H, Hou PN, Gao L, Du RL, Zhang XD. Nemo-like kinase is critical for p53 stabilization and function in response to DNA damage. Cell Death Differ. 2014;21:1656–63. doi:10.1038/cdd.2014.78.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Zhang ZY, Li SZ, Zhang HH, Wu QR, Gong J, Liang T, Gao L, Xing NN, Liu WB, Du RL, Zhang XD. Stabilization of ATF5 by TAK1-Nemo-like kinase critically regulates the interleukin-1β-stimulated C/EBP signaling pathway. Mol Cell Biol. 2015;35:778–88. doi:10.1128/MCB.01228-14.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Zhou X, Ren Y, Zhang J, Zhang C, Zhang K, Han L, Kong L, Wei J, Chen L, Yang J, Wang Q, Zhang J, Yang Y, Jiang T, Li M, Kang C. HOTAIR is a therapeutic target in glioblastoma. Oncotarget. 2015;6:8353–65. doi:10.18632/oncotarget.3229.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Division of Cell Regulation Systems, Medical Institute of BioregulationKyushu UniversityFukuokaJapan
  2. 2.Institute for Molecular and Cellular RegulationGunma UniversityMaebashiJapan